Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Evaluation of two SARS-CoV-2 immunoassays
Aim: The purpose of this study is to verify the performance of the Roche Elecsys ® antinucleocapsid (qualitative) and anti-spike (quantitative) SARS-CoV-2 immunoassays to determine whether the performance of the assays is acceptable for diagnostic use in the Groote Schuur Hospital virology/chemistry...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Thesis |
| Language: | English |
| Published: |
Department of Clinical Laboratory Sciences
2023
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
| _version_ | 1867613162298146816 |
|---|---|
| access_status_str | Open Access |
| author | Naidoo, Michelle |
| author2 | Hardie, Diana |
| author_browse | Hardie, Diana Naidoo, Michelle |
| author_facet | Hardie, Diana Naidoo, Michelle |
| author_sort | Naidoo, Michelle |
| collection | Thesis |
| description | Aim: The purpose of this study is to verify the performance of the Roche Elecsys ® antinucleocapsid (qualitative) and anti-spike (quantitative) SARS-CoV-2 immunoassays to determine whether the performance of the assays is acceptable for diagnostic use in the Groote Schuur Hospital virology/chemistry laboratory, as well as other National Health Laboratory Service (NHLS) laboratories in South Africa. Methods: We performed a verification study using de-identified remnant serum or plasma samples. Standard verification experiments including sensitivity, specificity and precision were performed. Pre-pandemic samples were used to assess specificity. Samples with a linked positive SARS-CoV-2 polymerase chain reaction (PCR) result on a respiratory sample >10 days before the serum/plasma collection date were used to assess sensitivity. Additionally, postvaccine humoral response and other parameters was assessed in a cohort of laboratory staff. Results: For the anti-nucleocapsid antibody assay, specificity was 99.7% based on 316 samples and sensitivity 91.3% based on 404 samples. For the anti-spike antibody assay, the specificity based on 194 samples was 100%, and the sensitivity based on 384 samples was 93.8%. Both assays demonstrated acceptable precision. Furthermore, the anti-spike antibody assay sensitivity was >92% during the first three waves in South Africa, dominated by different SARS-CoV-2 variants. Post-vaccine seroconversion in 115 staff with no evidence of prior natural infection was 99% and hybrid immunity produced higher anti-spike antibody titres compared to vaccine-only participants. Conclusion: Both immunoassays met our acceptance criteria. Both assays can be used for seroprevalence studies. The anti-nucleocapsid immunoassay assay is valuable in confirming past natural infection in patients with previous asymptomatic infection, previous symptomatic infection where no PCR was done or PCR-negative patients who present to hospital with COVID-19 during the second week of illness or later. Most importantly, the antispike immunoassay can be used as a reliable, cheap, and easily accessible surrogate marker of post-vaccine humoral immune response and we recommend using this to confirm and monitor humoral immune response in patients with risk factors for non-seroconversion following vaccination and increased risk for morbidity and mortality following infection with SARS-CoV-2. |
| format | Thesis |
| id | oai:open.uct.ac.za:11427/37603 |
| institution | University of Cape Town (South Africa) |
| language | eng |
| last_indexed | 2026-06-10T12:31:45.395Z |
| license_str | Not specified — see source repository |
| provenance_str_mv | Harvested via OAI-PMH from UCTD — University of Cape Town Open Access Repository |
| publishDate | 2023 |
| publishDateRange | 2023 |
| publishDateSort | 2023 |
| publisher | Department of Clinical Laboratory Sciences |
| publisherStr | Department of Clinical Laboratory Sciences |
| record_format | dspace |
| source_str | UCTD — University of Cape Town Open Access Repository |
| spelling | oai:open.uct.ac.za:11427/37603 Evaluation of two SARS-CoV-2 immunoassays Naidoo, Michelle Hardie, Diana laboratory sciences Aim: The purpose of this study is to verify the performance of the Roche Elecsys ® antinucleocapsid (qualitative) and anti-spike (quantitative) SARS-CoV-2 immunoassays to determine whether the performance of the assays is acceptable for diagnostic use in the Groote Schuur Hospital virology/chemistry laboratory, as well as other National Health Laboratory Service (NHLS) laboratories in South Africa. Methods: We performed a verification study using de-identified remnant serum or plasma samples. Standard verification experiments including sensitivity, specificity and precision were performed. Pre-pandemic samples were used to assess specificity. Samples with a linked positive SARS-CoV-2 polymerase chain reaction (PCR) result on a respiratory sample >10 days before the serum/plasma collection date were used to assess sensitivity. Additionally, postvaccine humoral response and other parameters was assessed in a cohort of laboratory staff. Results: For the anti-nucleocapsid antibody assay, specificity was 99.7% based on 316 samples and sensitivity 91.3% based on 404 samples. For the anti-spike antibody assay, the specificity based on 194 samples was 100%, and the sensitivity based on 384 samples was 93.8%. Both assays demonstrated acceptable precision. Furthermore, the anti-spike antibody assay sensitivity was >92% during the first three waves in South Africa, dominated by different SARS-CoV-2 variants. Post-vaccine seroconversion in 115 staff with no evidence of prior natural infection was 99% and hybrid immunity produced higher anti-spike antibody titres compared to vaccine-only participants. Conclusion: Both immunoassays met our acceptance criteria. Both assays can be used for seroprevalence studies. The anti-nucleocapsid immunoassay assay is valuable in confirming past natural infection in patients with previous asymptomatic infection, previous symptomatic infection where no PCR was done or PCR-negative patients who present to hospital with COVID-19 during the second week of illness or later. Most importantly, the antispike immunoassay can be used as a reliable, cheap, and easily accessible surrogate marker of post-vaccine humoral immune response and we recommend using this to confirm and monitor humoral immune response in patients with risk factors for non-seroconversion following vaccination and increased risk for morbidity and mortality following infection with SARS-CoV-2. 2023-03-31T07:34:23Z 2023-03-31T07:34:23Z 2022 2023-03-31T07:33:39Z Master Thesis Masters MMed http://hdl.handle.net/11427/37603 eng application/pdf Department of Clinical Laboratory Sciences Faculty of Health Sciences |
| spellingShingle | laboratory sciences Naidoo, Michelle Evaluation of two SARS-CoV-2 immunoassays |
| thesis_degree_str | Master's |
| title | Evaluation of two SARS-CoV-2 immunoassays |
| title_full | Evaluation of two SARS-CoV-2 immunoassays |
| title_fullStr | Evaluation of two SARS-CoV-2 immunoassays |
| title_full_unstemmed | Evaluation of two SARS-CoV-2 immunoassays |
| title_short | Evaluation of two SARS-CoV-2 immunoassays |
| title_sort | evaluation of two sars cov 2 immunoassays |
| topic | laboratory sciences |
| url | http://hdl.handle.net/11427/37603 |
| work_keys_str_mv | AT naidoomichelle evaluationoftwosarscov2immunoassays |